Therapeutic Performance Evaluation of <sup>213</sup>Bi-Labelled Aminopeptidase N (APN/CD13)-Affine NGR-Motif ([<sup>213</sup>Bi]Bi-DOTAGA-cKNGRE) in Experimental Tumour Model: A Treasured Tailor for Oncology

Therapeutic Performance Evaluation of <sup>213</sup>Bi-Labelled Aminopeptidase N (APN/CD13)-Affine NGR-Motif ([<sup>213</sup>Bi]Bi-DOTAGA-cKNGRE) in Experimental Tumour Model: A Treasured Tailor for Oncology

Since NGR-tripeptides (asparagine-glycine-arginine) selectively target neoangiogenesis-associated Aminopeptidase N (APN/CD13) on cancer cells, we aimed to evaluate the in vivo tumour targeting capability of radiolabelled, NGR-containing, ANP/CD13-selective [<sup>213</sup>Bi]Bi-DOTAGA-cKN...

Full description

Bibliographic Details
Main Authors: Zita Képes, Viktória Arató, Judit P. Szabó, Barbara Gyuricza, Dániel Szücs, István Hajdu, Anikó Fekete, Frank Bruchertseifer, Dezső Szikra, György Trencsényi
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Pharmaceutics
Subjects:
APN/CD13 (Aminopeptidase N)
[<sup>213</sup>Bi]Bi-DOTAGA-cKNGRE
fibrosarcoma
HT1080
NGR (asparagine-glycine-arginine)
positron emission tomography (PET)
Online Access:https://www.mdpi.com/1999-4923/15/2/491

Internet

https://www.mdpi.com/1999-4923/15/2/491

Similar Items